Recent studies have reported that Staphylococcus aureus small colony variants (SCVs) can cause highly persistent infections in humans and in cultured endothelial cells. To understand the process by which SCVs of S. aureus appear in subjects who have not received antibiotic treatment, bovine endothelial cells were coincubated with a wild S. aureus strain for 72 h in the presence of lysostaphin. Intracellular bacteria were harvested and screened for stable SCVs. Intracellular bacteria developed the SCV phenotype at a greater rate than control bacteria not exposed to endothelial cells: The intracellular induction rate was~10-3 versus a spontaneous rate of <10-7
Small colony variants (SCVs) of Staphylococcus aureus are found in patients with infections that persist despite appropriate antibiotic treatment or that recur after long disease-free intervals [I, 2] . SCVs are usually isolated from patients who have been receiving antibiotics, and several in vitro and in vivo studies have demonstrated that aminoglycosides produce the SCV phenotype from S. aureus [3] . However, SCYs have also been recovered from humans with staphylococcal infections in the absence of antibiotic pressure [I, 2] and from animals with experimental endocarditis [4] , Here we used an in vitro model for endovascular persistence [5] to assess whether SCYs of S. aureus are generated inside endothelial cells (ECs) at a greater rate than the spontaneous rate observed under control conditions [6] .
Materials and Methods
Bacterial inoculum preparation. S. aureus 6850 was the parent strain in all experiments. Bacterial inoculum (10 8 /mL) was counted in a Petroff-Hausser chamber as described [3, 7] , and viability was tested by plating in duplicate 10- and plated in duplicate on TSA. The dilution containing the highest number of SCY s (30-300 cfu/ streak) was counted, although SCYs were screened through all three dilutions. The spontaneous SCY formation rate was calculated as in the intracellular experiments. To determine whether lysostaphin enhanced SCY production, 13 culture tubes containing a range of enzyme concentrations (I: 10 successive dilutions from 100 jig/mL to 1.0 fg/mL and a control without lysostaphin) in 10 mL of tryptic soy broth (Difco) and 10 7 bacteria/mL were incubated for 24 h in air at 35°C. Four 100-ILL samples from each of three dilutions were plated per tube, and cfu were counted and SCVs screened as detailed above. This experiment was repeated three times. In addition, to find the number of stable SCVs in any starting S. aureus 6850 culture, 1 mL of bacteria (10 710g phase growing cells) not previously exposed to gentamicin was plated on TSA containing four times the MIC for the wild type strain. Growth of stable SCVs at the concentration at which wild type bacteria do not survive represents the spontaneous number of variants initially present in the original inoculum. This experiment was repeated three times.
Characterization ofSCV strains. All stable SCV isolates were tested for auxotrophism by using diffusion disks on TSA containing 2.0 /-lg of menadione or 20 /-lg of hemin and by growing in the presence of 5% CO 2 [3] . Gram's stain characteristics, hemolytic activity (sheep blood agar; Difco), coagulase production (tube coagulase test; GIBCO BRL, Gaithersburg, MD), and susceptibility tests for lysostaphin and gentamicin were evaluated by standard procedures.
Statistical analysis. We used the z-test with Yates's correction to compare proportions between intracellular and control SCV formation rates in 34 experiments.
Results
Before ECs were infected, 100 /-lL from the inoculum (l0 8 bacteria/mL) was plated to evaluate bacterial viability (31% ± 7% of 10 7 bacteria/mL of ECs = 3.1 ± 0.7 X 10 6 viable bacteria/mL) and to screen for the presence of spontaneous SCVs at time zero (table 1) . On average, 310 ± 70 cfu were counted per streak at the 10-5 dilution, giving a total of 25,000 cfu from 34 experiments. Stable SCVs were not found in this or in the two higher dilutions (2500 additional cfu screened). Based on the absolute number of cfu screened, we found <3. Considering that only one stable SCV cfu was selected by gentamicin, the spontaneous rate of SCVs was 1.11 X 10-
7
(1/9.0 X 10 6 ) (table 1). Table 2 shows the biochemical characterization of the SCV strains. There were 9 (64%) menadione auxotrophs and 3 (22%) NOTE. M = menadione, H = hemin, NS = nonsupplemented, S = supplemented with menadione or CO" NT = not tested because of nonauxotrophism.
*No. of cfu for each strain.
CO 2 auxotrophs, and 2 (14%; E3-2 and E4-10) showed no auxotrophism for hemin, menadione, or CO 2 • Growth was enhanced by 5% CO 2 incubation in all of the menadione-auxotrophic strains, and growth of the CO 2 auxotrophs was enhanced by menadione in I (E3-8). Ten (71%) were nonhemolytic; the other 4 were weakly hemolytic. When the auxotrophy was relieved with menadione or CO 2 (12 strains), 8 strains (66.7%)
showed the same hemolytic activity as that of S. aureus 6850, I (8.3%) showed significant but weaker hemolysis than the parent strain, and 3 (25%) remained weakly hemolytic even when they were supplemented. Hemolytic activity correlated with the degree of reversion to the parent strain phenotype that each SCV strain achieved once the auxotrophy was relieved, with stronger hemolysis in the strains that regained full growth rate and pigmentation.
Further phenotypic characterization of the SCVs revealed that all strains formed grape-like clusters and were gram-and coagulase-positive when the auxotrophy was relieved. However, SCVs showed a greater tendency toward being gramvariable, exhibited smaller elliptical cocci and less microc1us-tering, and were coagulase-negative in the absence of menadione or CO 2 • Exceptions were strains E3-2 and E4-1O, which did not show auxotrophism for the compounds tested but were coagulase-positive as SCVs (table 2) .
All SCV strains, like the parent strains, were fully susceptible to 2.0 f..lg of lysostaphin/mL. Lysostaphin does not induce the SCV phenotype at sub-MICs between 1.0 fg/mL and 100 ng/ ml., and the number of cfu after 24 h of incubation was the same as control cultures without lysostaphin. A total of 12,000 cfu were screened in three experiments.
Discussion
The intracellular rate of stable SCV formation is four orders of magnitude greater than the rate obtained by gentamicin selection, Because gentamicin on agar kills wild type organisms while allowing SCVs already present on the inoculum to survive, it selects for the rare spontaneous event (~I SCV in 10 7 organisms). In contrast, finding 1 SCV in every 1000 cfu recovered from cultured EC (14/14,000) suggests that induction, rather than selection, has occurred. The abrupt appearance of SCVs between 48 and 72 h, with the lack of stable SCVs before 48 h, also supports the concept of intracellular induction of variants. If selection were occurring, a steady increase in cfu would have been found.
There may be a connection between SCV intracellular induction, intracellular persistence, and the pathophysiology of some S. aureus infections. In vitro experimentation [10, 11] suggests that the EC intracellular milieu protects slow-growing organisms from cell-mediated immunity. In addition, the intracellular space is reached only to a limited extent by ,8-lactams and aminoglycosides [12] . Even antibiotics with excellent intracellular concentrations and high in vitro antistaphylococcal activity, such as erythromycin and c1indamycin, are not effective against intracellular S. aureus [13] . Furthermore, a recent evaluation of the bactericidal activity of antistaphylococcal antibiotics inside ECs [14] found surprising differences between conventional and intracellular MBCs: In the intracellular milieu for vancomycin, rifampin, and ciprofloxacin, respectively, these were 1024, 128, and 8 times higher [12, 13] . Independent of their localization with respect to the host cell, SCVs are more difficult to treat because of their slow growth [2, IS] . Antibiotics that require a metabolically active target are not as effective against SCVs (aminoglycosides [I, 3, 10] and ,8-lactams [1, 10, 15] ). These advantages may permit S. aureus SCVs to survive much longer intracellularly, to revert to the parent strain, and to invade new tissues, thus perpetuating infection and producing late relapses [I, 2].
